

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1057027
<b>Application Number:</b>	09889227
<b>Confirmation Number:</b>	5714
<b>Title of Invention:</b>	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Pamela Richardson
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 15(1)
<b>Receipt Date:</b>	24-MAY-2006
<b>Filing Date:</b>	08-JAN-2002
<b>Time Stamp:</b>	16:33:56
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	NPL Documents	AdjeietalAphaselstudy.pdf	69532	no	1

<b>Warnings:</b>					
<b>Information:</b>					
2	NPL Documents	AhmadetalKinaseInhibition.pdf	590309	no	5
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	AuclairetalBAY43-9006.pdf	59931	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Bankstonetal.pdf	365909	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Bollagetal.pdf	525209	no	6
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	BoltonetalRasOncogene.pdf	1260624	no	10
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	BosrasOncogenes.pdf	903184	no	8
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	CampbelletalIncreasingComplexity.pdf	2424350	no	19
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Carlingetal1-3-Cyanobenzyl.pdf	1122337	no	10
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	carteretal.pdf	173325	no	1

<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	ChangetalBay43-9006sorafenib.pdf	73262	no	1
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	ClarketalSafetyandPharmacokinetics.pdf	1034920	no	9
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Cunninghametal.pdf	529224	no	7
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	DansonetalImprovingOutcomes.pdf	859338	no	11
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	DaumetalTheinsandouts.pdf	314709	no	3
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	DeGrendeleH.pdf	222928	no	3
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	DumasSynthesisandpharmacological.pdf	337191	no	4
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	DumasDiscoverofanewclassp38.pdf	269973	no	4
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Dumasetal1-Phenyl.pdf	281356	no	4

<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Dumasprotienkinaseinhib.pdf	750454	no	10
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			12168065		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p>					